Online inquiry

IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5454MR)

This product GTTS-WQ5454MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets tcdA gene. The antibody can be applied in Clostridium difficile infectious diarrhea research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq WP_009902072.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57299391
UniProt ID P16154
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ5454MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2111MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ4198MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIIB019
GTTS-WQ147MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ1709MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ13776MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-1033
GTTS-WQ15819MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ14024MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-3500
GTTS-WQ12447MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA NKTR-214
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW